Gates-backed Ex­i­cure wraps 2016 with its first ma­jor col­lab­o­ra­tion and a plan for the year ahead

Ex­i­cure has crossed a few key items off the to-do list that dom­i­nates the ex­is­tence of every up­start biotech. And it’s wrap­ping up 2016 with a rite of pas­sage that helps po­si­tion it for a New Year filled with pipeline build­ing plans and new part­ner­ship hunts.

This morn­ing the Chica­go-based biotech is an­nounc­ing that it has com­plet­ed its first in­dus­try col­lab­o­ra­tion, pass­ing along its lead drug that has just suc­cess­ful­ly nav­i­gat­ed a small proof-of-con­cept study in pso­ri­a­sis. Pur­due Phar­ma is step­ping in with a pact — worth up to $790 mil­lion if all the cards turn in its fa­vor — that will give it con­trol of a Phase II-ready pso­ri­a­sis drug along with three more pro­grams to be de­cid­ed lat­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.